{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:14:28Z","timestamp":1772241268952,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000948","name":"Pfizer Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005205","name":"AstraZeneca Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.cllc.2020.01.007","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T20:28:02Z","timestamp":1583526482000},"page":"378-383.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes"],"prefix":"10.1016","volume":"21","author":[{"given":"Brandon","family":"Lau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2020.01.007_bib1","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2020.01.007_bib2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.critrevonc.2012.03.001","article-title":"The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma","volume":"84","author":"Linton","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.cllc.2020.01.007_bib3","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.lungcan.2015.03.005","article-title":"Demographics, management and survival of patients with malignant pleural mesothelioma in the National Lung Cancer Audit in England and Wales","volume":"88","author":"Beckett","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2020.01.007_bib4","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/bjc.2014.478","article-title":"Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales","volume":"111","author":"Linton","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.cllc.2020.01.007_bib5","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1445-5994.2012.02925.x","article-title":"Patterns of care for malignant pleural mesothelioma patients compensated by the Dust Disease Board in New South Wales, Australia","volume":"43","author":"Kao","year":"2013","journal-title":"Intern Med J"},{"key":"10.1016\/j.cllc.2020.01.007_bib6","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.01.007_bib7","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2020.01.007_bib8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2020.01.007_bib9","first-page":"428","article-title":"Systematic review of trimodality therapy for patients with malignant pleural mesothelioma","volume":"1","author":"Cao","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"10.1016\/j.cllc.2020.01.007_bib10","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.01.007_bib11","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2020.01.007_bib12","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1001\/jama.291.22.2720","article-title":"Participation in cancer clinical trials: race-, sex-, and age-based disparities","volume":"291","author":"Murthy","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.cllc.2020.01.007_bib14","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/1471-2407-9-130","article-title":"Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trials","volume":"9","author":"Vardy","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.cllc.2020.01.007_bib15","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/annonc\/mdr443","article-title":"The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials","volume":"23","author":"Clarey","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2020.01.007_bib16","series-title":"World Health Organisation Classification of Tumours","article-title":"Pathology and genetics of tumours of the lung, pleura, thymus and heart","author":"Travis","year":"2004"},{"key":"10.1016\/j.cllc.2020.01.007_bib17","first-page":"38","article-title":"Prophylactic procedure tract radiotherapy for malignant pleural mesothelioma: a systematic review and meta-analysis","volume":"13","author":"Bergamin","year":"2018","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.cllc.2020.01.007_bib18","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2020.01.007_bib19","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1136\/thoraxjnl-2017-211321","article-title":"British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma","volume":"73","author":"Woolhouse","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.cllc.2020.01.007_bib20","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.jtho.2017.05.024","article-title":"Tumor suppressor microRNAs contribute to the regulation of PD-L1 expression in malignant pleural mesothelioma","volume":"12","author":"Kao","year":"2017","journal-title":"J\u00a0Thorac Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.cllc.2020.01.007_bib21","first-page":"mdz394.091","article-title":"A\u00a0multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy for advanced pre-treated malignant pleural mesothelioma (MPM): results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"30","author":"Popat","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2020.01.007_bib22","series-title":"Pembrolizumab in performance status 2 patients with non-small-cell lung cancer (NSCLC): results of the PEPS2 trial","author":"Middleton","year":"2018"},{"key":"10.1016\/j.cllc.2020.01.007_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/sj.bjc.6604442","article-title":"Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials","volume":"99","author":"Ceresoli","year":"2008","journal-title":"Br J Cancer"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420300073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730420300073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:10:01Z","timestamp":1761505801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730420300073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S1525730420300073"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2020.01.007","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Trials Eligibility of Patients With Malignant Pleural Mesothelioma: Use of Novel Therapies and Outcomes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2020.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}